Showing 2749 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for…
-
Press release /Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate…
-
Press release /Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious…
-
Press release /New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,…
-
Clinical Trials /
-
Story /Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.
-
Biography /